VX18-445-106-Part B: A Phase 3, Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Project: Research project

Project Details

StatusActive
Effective start/end date8/9/19 → 8/31/50

Funding

  • Vertex Pharmaceuticals Incorporated
View all
View less